Close Menu

Pronto Diagnostics

The deal covers MNG's complete line of neurogenetic clinical RNA sequencing services, including complete transcriptome sequencing.

The Israeli molecular diagnostics company will use artificial intelligence and phenotypic analysis to increase the diagnostic rate of its genetic tests.

By Molika Ashford
In the hunt for the genetic causes of hearing loss in local populations, researchers at Tel Aviv University have taken up targeted genomic capture and deep sequencing to root out causative mutations.

Pronto will begin offering the test to the private payor market and begin the regulatory process to make the test available to the publicly funded Israeli HMO market.

Signal Genetics' CEO J said the deal "represents our initial entry into the international market with MyPRS and strong interest among both laboratories and physicians outside the United States in providing broader access to this novel technology."

Starting in November, Pronto Diagnostics plans to begin marketing in Israel Epigenomics' Septin 9-based test for early detection of colorectal cancer

Pronto, based in Tel Aviv, is the first distributor for Epi proColon outside of Germany, where Epigenomics is headquartered.

Pronto will begin marketing Epigenomics' Epi proColon test in November.

Nature News examines how science in the UK may fare as Boris Johnson, the next prime minister, pursues Brexit.

CNN reports that Immigration and Customs Enforcement in the US has expanded its DNA testing to seven sites along the southern border.

In PNAS this week: role for exosomes in neuronal circuit development, tuberculosis pathogen enzymes, and more.

Undoing Obamacare protections could affect people's willingness to undergo genetic testing, Sarah Lawrence College's Laura Hercher and the University of Iowa College of Law's Anya Prince write at BuzzFeed News.